Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Future directions for multiple myeloma treatment

Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, gives an overview of the evolving treatment paradigm for multiple myeloma patients. Dr Martin discusses the potential development of a cure for myeloma in the future, highlighting emerging results from studies investigating CAR T-cell therapies for patients with relapsed/refractory myeloma, and the possible impact of bringing these into a frontline setting. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.


Research funding to institution: Sanofi, Janssen, AMGEN
Consultancy: GSK